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Postapproval Safety and Efficacy of Transcarotid Arterial Revascularization
Objectives: Transcarotid arterial revascularization (TCAR) is a hybrid, less invasive, technique for revascularization of high-risk patients using flow reversal for neuroprotection. The ROADSTER trial demonstrated safety and stroke risk reduction in a trial setting. The purpose of this study is to evaluate the outcomes of this technique in a real-world setting after Food and Drug Administration approval.
Methods: Patients were eligible for TCAR if they were considered high risk for surgical revascularization and had appropriate cervical anatomy. Consecutive postapproval cases were enrolled in a prospectively maintained registry. The primary end points were myocardial infarction, cerebrovascular accident, and death within 30 days of the procedure. Secondary outcomes included procedural success, duration of intervention, flow reversal time, and access site complications including cranial nerve injury.
Results: There were 88 patients who underwent TCAR between the two participating institutions (Table) . The mean age was 72.3 years, and 33 of the 88 (38%) were symptomatic. Significant medical history included hypertension in 82 (93%), diabetes mellitus in 32 (36%), and coronary artery disease in 49 (56%). Procedural success occurred in 86 of the 88 cases (98%), with one failed stent deployment and one failure to cross the lesion. All patients tolerated flow reversal. There were no myocardial infarctions or deaths within 30 days. One patient developed a postoperative stroke (1.1%.). The average procedure time was 91.7 6 4.46 standard error of the mean minutes with an average flow reversal time of 13.3 6 0.81 standard error of the mean minutes. There were no cranial nerve injuries and no access site complications.
Conclusions: In comparison with the ROADSTER trial, there were more symptomatic patients (26% vs 38%), with a similar profile of major comorbidities. The data demonstrate excellent safety with a single postoperative stroke. This study represents an initial postapproval experience with the TCAR technique, and serves to externally validate the procedural outcomes of the initial clinical trial. Objectives: Carotid endarterectomy (CEA) should be performed on symptomatic, surgically suitable patients who present a stenosis greater than 50% North American Symptomatic Carotid Endarterectomy Trial stenosis of the internal carotid artery within 14 days of their symptoms. Aim of this study was to evaluate the effects of Stroke Uni centralization for patients with symptomatic carotid stenosis undergoing CEA.
Methods: We conducted a single-institution review of consecutive patients who underwent CEA for symptomatic carotid stenosis 50% in the period between January 2014 and November 2017. Patients recruited had acute neurologic impairment on presentation, defined as <5 points on the National Institutes of Health Stroke Scale (NIHSS). They were divided in two groups if treated before (group A, 2014 to May 2016) or after (group B, June 2016 to November 2017) the establishment of a stroke unit. The 30-day neurologic status improvement was defined as a decrease (1) in the 30-day NIHSS score versus NIHSS score immediately 
